Drugs

Relenza (zanamivir) Information

Relenza (zanamivir) is an inhalation powder for oral inhalation approved for treatment of acute uncomplicated illness due to influenza A and B virus in adults and pediatric patients aged 7 years of age and older who have been symptomatic for no more than 2 days.

Relenza is indicated for preventive use (prophylaxis) in adults and pediatric patients aged 5 years of age and older.

Relenza is not a substitute for early influenza vaccination on an annual basis.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Contact FDA

Toll Free
(855) 543-3784, or
(301) 796-3400
Human Drug Information

Division of Drug Information (CDER)

Office of Communications

Feedback Form

10001 New Hampshire Avenue

Hillandale Building, 4th Floor

Silver Spring, MD 20993

Page Last Updated: 09/11/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English